Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 8, 2011, Pages 1796-1804

  Devaraj, Sridevi ^a   Tobias, Peter ^d   Kasinath, Balakuntalam S ^b   Ramsamooj, Rajendra ^a   Afify, Alaa ^a   Jialal, Ishwarlal ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

immune system; kidney; macrophages; microvascular complications; nephropathy

Indexed keywords

LAMININ; MYELOID DIFFERENTIATION FACTOR 88; NEPHRIN; PODOCIN; TOLL LIKE RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL COUNT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FLOW CYTOMETRY; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANIMALS; CHEMOKINES; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; KIDNEY; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; PODOCYTES; TOLL-LIKE RECEPTOR 2;

EID: 80051544616     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.228924     Document Type: Article

References (60)

1. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, Hsueh W, Rewers M, Roberts BT, Savage PJ, Skarlatos S, Wassef M, Rabadan-Diehl C. National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation. 2005; 111:3489-3493.
2. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes. 2006;55:774-779. (Pubitemid 43343235)
3. Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab. 2010;5:19-28.
4. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia. 2005;48:370-378. (Pubitemid 40543311)
5. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Dräger AM, Doni A, van Hinsbergh VW, Stehouwer CD. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999;42:351-357. (Pubitemid 29111443)
6. Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N, Aoki T. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes. 2007;56:2790-2796. (Pubitemid 350044923)
7. Andersen A, Christiansen J, Andersen J, Kreiner S, Deckert T. Diabetic nephropathy in type I (insulin-dependent) diabetes: an epidemiological study, Diabetologia. 1983;25:496-501. (Pubitemid 14200886)
8. Krolewski M, Eggers P, Warram J. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study, Kidney Int. 1996;50:2041-2046. (Pubitemid 26417548)
9. US Renal Data System. USRDS Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
10. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 2008;74:22-36. (Pubitemid 351841893)
11. Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis. 1993;21:480-485. (Pubitemid 23160508)
12. Sassy-Prigent C, Heudes D, Mandet C, Belair MF, Michel O, Perdereau B, Bariety J, Bruneval P. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes. 2000;49:466-475. (Pubitemid 30131794)
13. Mora C, Navarro JF. The role of inflammation as a pathogenic factor in the development of renal disease in diabetes. Curr Diab Rep. 2005;5: 399-401. (Pubitemid 43020005)
14. Grieco FA, Vendrame F, Spagnuolo I, Dotta F. Innate immunity and the pathogenesis of type 1 diabetes. Semin Immunopathol. 2011;33:57-66.
15. Pino SC, Kruger AJ, Bortell R. The role of innate immune pathways in type 1 diabetes pathogenesis. Curr Opin Endocrinol Diabetes Obes. 2010;17:126-130.
16. Devaraj S, Jialal I, Yun JM, Bremer A. Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications. Metabolism. 2011;60:256-259.
17. Zipris D. Toll-like receptors and type 1 diabetes. Adv Exp Med Biol. 2010;654:585-610.
18. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135-145. (Pubitemid 33741967)
19. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab. 2008;93:578-583. (Pubitemid 351240834)
20. Devaraj S, Dasu MR, Park SH, Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia. 2009;52: 1665-1668.
21. Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol. 2010; 6:224-235.
22. Brown HJ, Sacks SH, Robson MG. Toll-like receptor 2 agonists exacerbate accelerated nephrotoxic nephritis. J Am Soc Nephrol. 2006;17: 1931-1939. (Pubitemid 44036177)
23. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, Barnes JL, Kasinath BS. Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am J Pathol. 2007;171:1733-1742.
24. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, Camussi G. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes. 2003;52:1023-1030. (Pubitemid 36384273)
25. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med. 2006;354: 1387-1401.
26. Foster RR, Saleem MA, Mathieson PW, Bates DO, Harper SJ. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol. 2005;288:F48-F57. (Pubitemid 40038675)
27. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-. J Clin Invest. 1994;93:536-542. (Pubitemid 24072793)
28. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGFαas the major mediator. J Am Soc Nephrol. 2004;15:S55-S57. (Pubitemid 38018457)
29. Kolb H. Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes Metab Rev. 1987;3:751-778. (Pubitemid 17112110)
30. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453-461. (Pubitemid 351599757)
31. Devaraj S, Jialal I. C-reactive protein polarizes human macrophages to an m1 phenotype and inhibits transformation to the m2 phenotype. Arterioscler Thromb Vasc Biol. 2011;31:1397-1402.
32. Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes. 2008;57:3090-3098.
33. Hayat MA. Principles and Techniques of Electron Microscopy Biological Applications. Boca Raton, FL: CRC Press; 1989.
34. Karnovsky MJ. A formaldehyde-glutaraldehyde fixative of high osmolality for use in electron microscopy. J Cell Biol. 1965;27:137A-40A.
35. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65:116-128. (Pubitemid 38037496)
36. Brosius FC III, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakuki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, Takahashi T. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009;20: 2503-2512.
37. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433-442. (Pubitemid 351355386)
38. Fornoni A, Ijaz A, Tejada T, Lenz O. Role of inflammation in diabetic nephropathy. Curr Diabetes Rev. 2008;4:10-17. (Pubitemid 351216880)
39. Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, Kirschning CJ, Akira S, van der Poll T, Weening JJ, Florquin S. Renalassociated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest. 2005;115:2894-2903. (Pubitemid 41434417)
40. Pulskens WP, Teske GJ, Butter LM, Roelofs JJ, van der Poll T, Florquin S, Leemans JC. Toll-like receptor-4 coordinates the innate immune response of the kidney to renal ischemia/reperfusion injury. PLoS One. 2008;3:e3596-e3599.
41. Allen TJ, Cooper ME, Lan HY. Use of genetic mouse models in the study of diabetic nephropathy. Curr Diab Rep. 2004;4:435-440. (Pubitemid 40104219)
42. Breyer MD, Bottinger E, Brosius FC III, Coffman TM, Harris RC, Heilig CW, Sharma K. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16:27-45. (Pubitemid 43073154)
43. Bilous R. Renal structural damage in IDDM and NIDDM functional relationships. In: Hasslacher C, ed. Diabetic Nephropathy. Chichester, West Sussex, United Kingdom: John Wiley & Sons; 2001:71-89.
44. Maeda M, Yabuki A, Suzuki S, Matsumoto M, Taniguchi K, Nishinakagawa H. Renal lesions in spontaneous insulin-dependent diabetes mellitus in the nonobese diabetic mouse: acute phase of diabetes. Vet Pathol. 2003;40:187-195. (Pubitemid 38393596)
45. Li J, Qu X, Yao J, Caruana G, Ricardo SD, Yamamoto Y, Yamamoto H, Bertram JF. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes. 2010;59:2612-2624.
46. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes. 2010;59:850-860.
47. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol. 2003;14:1358-1373. (Pubitemid 36519197)
48. Chen S, Hong SW, Iglesias-de la Cruz MC, Isono M, Casaretto A, Ziyadeh FN.The key role of the transforming growth factor-αsystem in the pathogenesis of diabetic nephropathy. Ren Fail. 2001;23:471-481. (Pubitemid 32692282)
49. Benigni A, Zoja C, Campana M, Corna D, Sangalli F, Rottoli D, Gagliardini E, Conti S, Ledbetter S, Remuzzi G. Beneficial effect of TGF-αantagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol. 206;104: 158-168.
50. Bonnet F, Tikellis C, Kawachi H, Burns WC, Wookey PJ, Cao Z, Cooper ME. Nephrin expression in the post-natal developing kidney in normotensive and hypertensive rats. Clin Exp Hypertens. 2002;4:371-381. (Pubitemid 34743400)
51. Cooper ME, Mundel P, Boner G. Role of nephrin in renal disease including diabetic nephropathy. Semin Nephrol. 2002;22:393-398. (Pubitemid 35024515)
52. Menne J, Meier M, Park JK, Boehne M, Kirsch T, Lindschau C, Ociepka R, Leitges M, Rinta-Valkama J, Holthofer H, Haller H. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C-signaling in-vivo. Kidney Int. 2006;70:1456-1462. (Pubitemid 44527315)
53. Welsh GI, Saleem MA. Nephrin-signature molecule of the glomerular podocyte? J Pathol. 2010;220:328-337.
54. Hodgkinson CP, Laxton RC, Patel K, Ye S. Advanced glycation endproduct of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:2275-2281.
55. Favre J, Musette P, Douin-Echinard V, Laude K, Henry JP, Arnal JF, Thuillez C, Richard V. Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2007;27:1064-1071. (Pubitemid 46641958)
56. Sakata Y, Dong JW, Vallejo JG, Huang CH, Baker JS, Tracey KJ, Tacheuchi O, Akira S, Mann DL. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;292:H503-H509. (Pubitemid 46105213)
57. Mohammad MK, Morran M, Slotterbeck B, Leaman DW, Sun Y, Grafenstein H, Hong SC, McInerney MF. Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol. 2006; 18:1101-1113. (Pubitemid 43923428)
58. Li F, Yang N, Zhang L, Tan H, Huang B, Liang Y, Chen M, Yu X. Increased expression of toll-like receptor 2 in rat diabetic nephropathy. Am J Nephrol. 2010;32:179-186.
59. Dasu MR, Thangappan RK, Bourgette A, DiPietro LA, Isseroff R, Jialal I. TLR2 expression and signaling-dependent inflammation impair wound healing in diabetic mice. Lab Invest. 2010;90:1628-1636.
60. Dasu MR, Riosvelasco A, and Jialal I. Candesartan inhibits Toll like receptor expression and activity both in vitro and in vivo. Atherosclerosis. 2009;202:76-83.